Navigation Links
Allos in Medical News

Industry Veterans Rash and Rutledge Launch RegionalCare Hospital Partners to Acquire and Operate Hospitals in Non-Urban Markets

...n approximately 600 companies in 30 countries. The firm has invested more than $6.5 billion in healthcare companies, including investments in allos Therapeutics, American Medical Systems, Bausch & Lomb, Coventry Health Care, Eurand, Euromedic International (acquired by Merrill Lynch Global Pri...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

... Corp. (Nasdaq: UTHR ) Valeant Pharmaceuticals Int'l (NYSE: VRX ) Vertex Pharmaceuticals (Nasdaq: VRTX ) Add Adolor Corp. (Nasdaq: ADLR ) allos THERAPEUTICS INC. (Nasdaq: ALTH ) Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY ) Alpharma Inc. (NYSE: ALO ) Altus Pharmaceuticals Inc. (Nasdaq:...

Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing

...iversity, Long Beach. "I am very excited to join allos and lead the Company's manufacturing activities," said Mr. Bennett. "I believe allos has the product candidates and leadership team to ...ew therapies for the treatment of cancer." About allos Therapeutics, Inc. ...

Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference

...ch will be accessible through a link posted on the allos website home page and investor relations section. ... Allos' website through December 28, 2007. About allos Therapeutics, Inc. allos Therapeutics is a biopharmaceutical company focuse...

Allos Therapeutics Reports Third Quarter 2007 Financial Results

...al 480-629-9562. Participants should reference the allos Therapeutics conference call. Conference Call Rep...llos.com and will be archived for 30 days. About allos Therapeutics, Inc. allos Therapeutics, Inc. (ALTH) is a biopharmaceutical c...

Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference

...be available for replay on Allos' website through November 20, 2007. About allos Therapeutics, Inc. allos Therapeutics is a biopharmaceutical company focused on the development and ...
Allos in Medical Technology

Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma

WESTMINSTER, Colo., Dec. 27 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH ) today announced that an independent Data Monitoring Committee (DMC) has completed the pre-specified 65-patient safety review of data from the Company's pivotal Phase 2 PROPEL trial of PDX (pralatrex...

Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma

PROPEL Enrollment Ahead of Schedule with Completion Expected Q2 2008 WESTMINSTER, Colo., Sept. 24 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH ) today announced the completion of pre-planned interim analyses of patient response and safety data from the Company's pivotal ...

William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman

...at Sofinnova Ventures and serves as Chairman of the Board of Directors at Intermune and a member of the Board of Directors of Inspire Pharmaceuticals, allos Therapeutics, Alvine Pharmaceuticals, Portola Pharmaceuticals, and BioCrossroads, a not for profit organization. Mr. Ringo holds a B.S. and an M.B.A. ...

Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma

...mphoma represents approximately 10 percent. About allos Therapeutics, Inc. allos Therapeutics, Inc. (ALTH) is a biopharmaceutical c...resentation, except as required by law. Note: The allos logo is a trademark of...

BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer

...t PARP-1 (poly-ADP-ribose polymerase), an enzyme crucial to cell repair and upregulated in certain tumors. Mr. Malek joins BiPar after seven years at allos Therapeutics where, as vice president of corporate development, he played a pivotal role in shifting Allos' strategy to focus solely on oncology asset...

Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma

...otrexate and certain other DHFR inhibitors. About allos Therapeutics, Inc. allos Therapeutics is a biopharmaceutical company focuse...resentation, except as required by law. Note: The allos logo is a trademark of...

Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European Commission

...irst-line or relapsed or refractory PTCLs. About allos Therapeutics, Inc. allos Therapeutics, Inc. (ALTH) is a biopharmaceutical c...pt as required by law. Note: EFAPROXYNTM and the allos logo are trademarks of Allos Therapeutics, Inc. ...

Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer

...1-689-8567. Call participants should reference the allos Therapeutics conference call. Conference Call Re...los.com and will be archived for 30 days. About allos allos Therapeutics, Inc. (ALTH) is a biopharmaceutical c...
Allos in Medical Definition

Allopathic medicine

...the symptoms. Often contrasted with homeopathy." [2] Other sources define allopathic medicine more in accord with the meaning of its word parts, allos meaning opposite and path meaning disease . Steadman's Medical Dictionary calls it a "therapeutic system in which a disease is treated by prod...
Allos in Biological Technology

OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development

...ale of that company to Sanofi-Aventis in April of this year. Previously, he held senior corporate development, marketing, and strategy positions with allos Therapeutics, Connetics Corporation, Abgenix and Gilead Sciences. Mr. Patel also served as a consultant with McKinsey & Company. Earlier in his ...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...SDAQ: ALXN ) ALKERMES INC. (NASDAQ: ALKS ) ALLERGAN INC. (NYSE: AGN ) allos THERAPEUTICS INC. (NASDAQ: ALTH ) ALNYLAM PHARMACEUTICALS INC. (NASDAQ: ...TM) Emerging Cancer Index (HHJ) Drop AETERNA ZENTARIS INC. (TSE: AEXS) allos THERAPEUTICS INC. (NASDAQ: ALTH ) ARQULE INC. (NASDAQ: ARQL ) ARRAY BIO...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)

...tics Corp. (Nasdaq: UTHR ) Valeant Pharmaceuticals Int'l (NYSE: VRX ) Vertex Pharmaceuticals (Nasdaq: VRTX ) Add Adolor Corp. (Nasdaq: ADLR ) allos THERAPEUTICS INC. (Nasdaq: ALTH ) Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY ) Alpharma Inc. (NYSE: ALO ) Altus Pharmaceuticals Inc. (Nasdaq: A...

Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

...e available for replay on Allos' website through February 22, 2008. About allos Therapeutics, Inc. allos Therapeutics is a biopharmaceutical company focused on the development and ...

Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference

...be available for replay on Allos' website through November 27, 2007. About allos Therapeutics, Inc. allos Therapeutics is a biopharmaceutical company focused on the development and ...

Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference

...s referenced above are available for review on the allos website (http://www.allos.com ) under the "Presen...Investor Relations" section of the website. About allos Therapeutics, Inc. allos Therapeutics, Inc. (ALTH) is a biopharmaceutical c...

Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference

... be available for replay on Allos' website through October 12, 2007. About allos Therapeutics, Inc. allos Therapeutics is a biopharmaceutical company focused on the development and ...

Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference

...e available for replay on Allos' website through September 21, 2007. About allos Therapeutics, Inc. allos Therapeutics is a biopharmaceutical company focused on the development and ...
Other Tags
(Date:4/17/2014)... the most popular vaccine brands for children may not ... overlooking some cost factors when choosing vaccines, driving the ... according to a new study by University of Illinois ... be driven by numerous factors," says Sheldon H. Jacobson, ... computer science and of mathematics at the U. of ...
(Date:4/17/2014)... Researchers at the University of California, San Diego School ... those who have suffered a recent major loss are ... older adults. , The study is published in this ... Psychiatry . , Because compassionate behaviors are associated with ... findings offer insights into ways to improve the outcomes ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... one in five infants in the United States annually ... several months after birth. Research into probiotic use for ... April 1, 2014 issue of the British Medical ... "Probiotics and Infant Colic," concluding that the use of ... did not reduce crying or fussing in infants ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
(Date:4/17/2014)... IPCC meeting painted a stark warning on the possible ... a greenhouse effect 32 times that of carbon dioxide. ... humic substances act as fully regenerable electron acceptors which ... in wetlands instead of being released to the atmosphere. ... disrupted it may enter into a vicious cycle to ...
(Date:4/17/2014)... Branch at Galveston are the first to recommend ... cancer should begin colorectal cancer screening earlier than ... a high incidence of secondary colorectal cancers among ... recommendations that the younger women in this group ... their initial cervical cancer diagnosis instead of waiting ...
(Date:4/17/2014)... a special feature of The Proceedings ... ) published April 29, raises a number of startling ... most of us take for granted. At the end ... around the globe shifted from hunting animals and gathering ... It seems so straightforward and yet the more scientists ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
Other Contents